Novel approaches to antimicrobial therapy: Peptide deformylase

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 785-792

  Waller, Andrew S ^a   Clements, John M ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Antibacterial; Antimicrobial; BB 83698; Drug resistance; Peptide deformylase; Peptide deformylase inhibitors

Indexed keywords

ACTINONIN; BACTERIAL PROTEIN; CHLORAMPHENICOL; FORMYLMETHIONINE; MACROLIDE; METALLOPROTEINASE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; POLYPEPTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIORPHAN; UNCLASSIFIED DRUG; VRC 4232; VRC 4307;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; APICOPLAST; BACTERIAL GENOME; CHLOROPLAST; CRYSTAL STRUCTURE; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME KINETICS; ESCHERICHIA COLI; GENE; GENE FMT; METAL BINDING; MINIMUM INHIBITORY CONCENTRATION; PLASMODIUM FALCIPARUM; PROTEIN SYNTHESIS; REVIEW; RIBOSOME; STREPTOCOCCUS PNEUMONIAE; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMIDOHYDROLASES; AMINOPEPTIDASES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; HYDROXAMIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036771389     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z: Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry (2000) 39(6):1256-1262. •• Reports that actinonin, a natural antibiotic, functions through inhibition of PDF.
2. Petrillo Jr EW, Ondetti MA: Angiotensin-converting enzyme inhibitors: Medicinal chemistry and biological actions. Med Res Rev (1982) 2(1):1-41
3. Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat. Pharmacol Ther (1997) 75(1):69-75.
4. Whittaker M, Floyd CD, Brown P, Gearing AJ: Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev (1999) 99(9):2735-2776.
5. Solbiati J, Chapman-Smith A, Miller JL, Miller CG, Cronan Jr JE: Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal. J Mol Biol (1999) 290(3):607-614.
6. Chang SY, McGary EC, Chang S: Methionine aminopeptidase gene of Escherichia coli is essential for cell growth. J Bacteriol (1989) 171(7):4071-4072.
7. Mazel D, Pochet S, Marliere P: Genetic characterisation of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J (1994) 13(4):914-923.
8. Meinnel T, Blanquet S: Evidence that peptide deformylase and methionyl-tRNA (fMet) formyltransferase are encoded within the same operon in Escherichia coli. J Bacteriol (1993) 175(23):7737-7740.
9. Becker A, Schlichting I, Kabsch W, Groche D, Schultz S, Wagner AF: Iron centre, substrate recognition and mechanism of peptide deformylase. Nat Struct Biol (1998) 5(12):1053-1058.
10. Ragusa S, Blanquet S, Meinnel T: Control of peptide deformylase activity by metal cations. J Mol Biol (1998) 280(3):515-523.
11. Rajagopalan PT, Pei D: Oxygen-mediated inactivation of peptide deformylase. J Biol Chem (1998) 273(35):22305-22310.
12. Becker A, Schlichting I, Kabsch W, Schultz S, Wagner AF: Structure of peptide deformylase and identification of the substrate binding site. J Biol Chem (1998) 273(19):11413-11416.
13. Chan MK, Gong W, Rajagopalan PT, Hao B, Tsai CM, Pei D: Crystal structure of the Escherichia coli peptide deformylase. Biochemistry (1997) 36(45):13904-13909.
14. Dardel F, Ragusa S, Lazennec C, Blanquet S, Meinnel T: Solution structure of nickel-peptide deformylase. J Mol Biol (1998) 280(3):501-513.
15. Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, Thomas W, Whittaker M, Wood S, Salama S, Baker PJ, Rodgers HF, Barynin V, Rice DW, Hunter MG: Antibiotic activity and characterisation of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother (2001) 45(2):563-570. •• Comprehensive analysis of the PDF inhibitor BB-3497; determination of co-crystal structures and its interaction with the enzyme target, spectrum of activity, in vitro/in vivo selectivity, time kill, resistance mechanisms and in vivo efficacy in a mouse model of septicemia.
16. Hu YJ, Wei Y, Zhou Y, Rajagopalan PT, Pei D: Determination of substrate specificity for peptide deformylase through the screening of a combinatorial peptide library. Biochemistry (1999) 38(2):643-650.
17. Huntington KM, Yi T, Wei Y, Pei D: Synthesis and antibacterial activity of peptide deformylase inhibitors. Biochemistry (2000) 39(15):4543-4551.
18. Wei Y, Yi T, Huntington KM, Chaudhury C, Pei D: Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library. J Comb Chem (2000) 2(6):650-657.
19. Meinnel T, Patiny L, Ragusa S, Blanquet S: Design and synthesis of substrate analogue inhibitors of peptide deformylase. Biochemistry (1999) 38(14):4287-4295.
20. Meinnel T: Developing a rational strategy for new antibacterial agents. Pathol Biol (Paris) (1999) 47(8):780-783.
21. Hackbarth CJ, Lopez S, Wang W, Jacobs J, Jain R, Ni ZJ, Trias J, Chen D, Withers G, Weidmann B, Patel DV, Yuan Z: Microbiological and enzymatic evaluation of deformylase inhibitors. 40th ICAAC Meeting, Toronto, ON, Canada (2000):Abs 2173.
22. Hackbarth CJ, Lopez S, Lewis JG, Wu C, Wang W, Withers G, Chen D, Jacobs J, Patel DV, White RJ, Trias J, Yuan Z: In vitro profile of N-alkyl urea hydroxamic acids that inhibit bacterial peptide deformylase. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-356. •• Details progress in identifying improved PDFIs and characterizes their in vitro activities and resistance profiles.
23. Chen D, Clark K, Cramer J, Mangold J, Koehn J, Lewis JG, Hackbarth C, Wu C, Wang W, Lopez S, Withers G et al: Preclinical analysis of N-alkyl urea hydroxamic acid peptide deformylase inhibitors. 41st ICAAC, Chicago, IL, USA (2001):Abs F-357.
24. Beckett P, Clements J, Davies S, Hunter M, Launchbury S, Pain G, Pratt L, Smith H, Spavold Z, Thomas W, Todd R, Whittaker M: Structure-activity relationships of the peptide deformylase inhibitor BB-3497. 41st ICAAC, Chicago, IL, USA (2001):Abs F-350. • Assessment of PDFI SAR and identification of BB-83698, an optimized PDFI with improved antibacterial activity.
25. Wise R, Andrews JM, Ashby J: In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob Agents Chemother (2002) 46(4):1117-1118.
26. Craig WA, Andes D: In vivo pharmacodynamics of BB-83698, a deformylase inhibitor. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-355. • Pharmacodynamic analysis of the first PDFI to enter rigorous testing in animal models of infection.
27. Azoulay-Dupuis E, Mohler J, Rieux V, Bédos J, Moine P, Carbon C: Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse pneumonia model induced by wild type and antimicrobial-resistant Streptococcus pneumoniae. 41st ICAAC Meeting, Chicago, IL, USA (2001):Abs F-354. • Demonstration of in vivo efficacy of PDFIs in lethal RTI infections resistant to conventional antibiotics.
28. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z, White R, Trias J: Peptide deformylase in Staphylococcus aureus: Resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother (2000) 44(7):1825-1831.
29. Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J: Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob Agents Chemother (2001) 45(9):2432-2435. •• Validates PDF as an excellent target in S pneumoniae and reviews PDF resistance mechanisms in other bacteria.
30. Giglione C, Serero A, Pierre M, Boisson B, Meinnel T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J (2000) 19(21):5916-5929. •• Discovery of eukaryotic PDF enzyme classes and their localization to cellular organelles.
31. Giglione C, Pierre M, Meinnel T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol (2000) 36(6):1197-1205.
32. Serero A, Giglione C, Meinnel T: Distinctive features of the two classes of eukaryotic peptide deformylases. J Mol Biol (2001) 314(4):695-708. • Characterization and identification of differences between the two forms of PDF within Arabidopsis thaliana.
33. Giglione C, Meinnel T: Peptide deformylase as an emerging target for antiparasitic agents. Exp Opin Ther Targets (2001) 5:41-57. •• Excellent review of the PDF enzyme class, including their catalytic mechanism and conservation in prokaryotic and eukaryotic organisms.
34. Chen D, Hackbarth C, Ni ZJ, Wang W, Wu C, Young D, White RJ, Trias J, Patel DV, Yuan Z: In vivo evaluation of VRC3375, a potent peptide deformylase inhibitor. 40th ICAAC Meeting, Toronto, ON, Canada (2000):Abs 2175. • In vivo efficacy and selectivity of a potent PDF inhibitor, validating the use of PDFIs as therapeutic agents.
35. Wiesner J, Sanderbrand S, Altincicek B, Beck E, Jomaa H: Seeking new targets for antiparasitic agents. Trends Parasitol (2001) 17(1):7-8. • Provides evidence that selective PDFIs may have potential as antimalarial agents.
36. Kumar A, Nguyen KT, Srivathsan S, Omstein B, Turley S, Hirsh I, Pei D, Hol WG: Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure (2002) 10(3):357-367.
37. VERSICOR INC (Patel DV): Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof. WO-09957097 (1999).
38. VERSICOR INC (Ni Z-J, Jacobs JW, Patel DV, Lewis J): Novel urea compounds, compositions and methods of use and preparation. WO-00144178 (2001).
39. BRITISH BIOTECH (Hunter MG, Beckett RP, Clements JM, Whittaker M, Davies SJ, Pratt LM, Spavold ZM, Launchbury S): Antibacterial agents. WO-09939704 (1999).